Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving viable micro-organism
Reexamination Certificate
2006-02-28
2006-02-28
Ketter, James (Department: 1636)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving viable micro-organism
C435S032000, C435S375000
Reexamination Certificate
active
07005274
ABSTRACT:
The present invention relates to improved diagnostic methods for early detection of a risk for developing an arthritic disorder in humans, and screening assays for therapeutic agents useful in the treatment of arthritic disorders, by comparing the levels of one or more indicators of altered mitochondrial function. Indicators of altered mitochondrial function include enzymes such as mitochondrial enzymes and ATP biosynthesis factors. Other indicators of altered mitochondrial function include mitochondrial mass, mitochondrial number and mitochondrial DNA content, cellular responses to elevated intracellular calcium and to apoptogens, and free radical production. Methods of treating, and of stratifying, human patients as such methods relate to disclosed indicators of altered mitchondrial function are also provided.
REFERENCES:
patent: 4846835 (1989-07-01), Grande
patent: 4870210 (1989-09-01), Musser
patent: 5041138 (1991-08-01), Vacanti et al.
patent: 5656450 (1997-08-01), Boyan et al.
patent: 5723331 (1998-03-01), Tubo et al.
patent: 5736372 (1998-04-01), Vacanti et al.
patent: 5786217 (1998-07-01), Tubo et al.
patent: 5840493 (1998-11-01), Davis et al.
patent: 5888498 (1999-03-01), Davis et al.
patent: 5902741 (1999-05-01), Purchio et al.
patent: 5928945 (1999-07-01), Seliktar et al.
patent: 5932459 (1999-08-01), Sittinger et al.
patent: 5935796 (1999-08-01), Fosang
patent: 745850 (1996-12-01), None
patent: WO 99/37294 (1999-07-01), None
patent: WO 99/55321 (1999-11-01), None
patent: WO 00/06150 (2000-02-01), None
Tabrizi et al. Secondary abnormalities of mitochondrial DNA associated with neurodegenerative disease. Biochem. Soc. Symp vol. 66 p99-110 2002.
Terkeltaub et al. Invited review: the mitochondrion in osteoarthritis. Mitochondrion vol. 1 pp301-319 2002.
Baker et al. The mechanism of chondrocyte hydrogen peroxide dambe. Depletion in intracellular ATP due to suppression of glycolysis caused by oxidation of glyceraldehyde-3-phosphate dehydrogenase. vol. 16 No. 1 1989 pp7-14.
Alevizopoulos et al., “Transforming Growth Factor-β: the Breaking Open of a Black Box,”BioEssays 19(7):581-591, Jul. 1997.
Al-Rubeai et al., “Cell Cycle, Cell Size and Mitochondrial Activity of Hybridoma Cells During Batch Cultivation,”Cytotechnology 7(3):179-186, Nov. 1991.
Anderson, “Mechanisms of Pathologic Calcification,”Rheum. Dis. Clin. North Amer. 14(2):303-319, Aug. 1988.
Anderson, “Molecular Biology of Matrix Vesicles,”Clin. Orthopaed. Rel. Res. 314:266-280, May 1995.
Ausserer et al., “Regulation of c-jun Expression During Hypoxic and Low-Glucose Stress,”Mol. Cell. Biol. 14(8):5032-5042, Aug. 1994.
Batinić-Haberle et al., “The Ortho Effect Makes Manganese(III) Meso-Tetrakis(N-Methylpyridinium-2-yl)Porphyrin a Powerful and Potentially Useful Superoxide Dismutase Mimic,”J. Biol. Chem. 273(38):24521-24528, Sep. 18, 1998.
Benya et al. “Dedifferentiated Chondrocytes Reexpress the Differentiated Collagen Phenotype When Cultured in Agarose Gels,”Cell 30(1):215-224, Aug. 1982.
Bisaccia et al., “Kinetic Characterization of the Reconstituted Tricarboxylate Carrier from Rat Liver Mitochondria,”Biochem Biophys Acta. 1019(3):250-256, Sep. 19, 1990.
Blanco et al., “Osteoarthritis Chondrocytes Die by Apoptosis. A Possible Pathway for Osteoarthritis Pathology,”Arthritis&Rheumatism 41(2):284-289, Feb. 1998.
Boskey et al., “Matrix Vesicles Promote Mineralization in a Gelatin Gel,”Calcif. Tissue Int. 60(3):309-315, Mar. 1997.
Boskey, “Matrix Proteins and Mineralization: an Overview,”Connect. Tissue Res. 35(1-4):357-363, 1996.
Clark et al., “Transforming Growth Factor-beta (TGF-β),”Int. J. Biochem. Cell. Biol. 30(3):293-298, Mar. 1998.
Crompton et al., “On the Involvement of a Mitochondrial Pore in Reperfusion Injury,”Basic Res. Cardiol. 88(5): 513-523, Sep.-Oct. 1993.
Day et al., “Metalloporphyrins are Potent Inhibitors of Lipid Peroxidation,”Free Radical Biology&Medicine 26(5-6):730-736, Mar. 1999.
Doherty, “Calcium Pyrophosphate in Joint Disease,”Hosp. Pract. 29(11):93-104, Nov. 15, 1994.
Doyle, “Tissue Calcification and Inflammation in Osteoarthritis,”J. Pathol. 136(3):199-216, Mar. 1982.
Dykens,Mitochondria&Free Radicals in Neurodegenerative Diseases, Beal, Howell and Bodis-Wollner, (Eds.), Wiley-Liss Inc., New York, 1997, Chapter 3, “Mitochondrial Free Radical Production and Oxidative Pathophysiology: Implications for Neurodegenerative Disease,” pp. 29-55.
Ernster et al., “Mitochondria: A Historical Review,”J. Cell. Biol. 91(3):227s-255s, Dec. 1981.
Farndale et al., “Improved Quantitation and Discrimination of Sulphated Glycosaminoglycans by Use of Dimethylmethylene Blue,”Biochim. Biophys. Acta 883(2):173-177, Sep. 4, 1986.
Fiermonte et al., “The Sequence, Bacterial Expression, and Functional Reconstitution of the Rat Mitochondrial Dicarboxylate Transporter Cloned via Distant Homologs in Yeast andCaenorhabditis elegans,” J. Biol. Chem. 273(38):24754-24759, Sep. 18, 1998.
Fiore et al., “The Mitochondrial ADP/ATP Carrier: Structural, Physiological and Pathological Aspects,”Biochimie 80:137-150, 1998.
Gilliland et al., “Disorders of the Joints and Connective Tissue,” Section 14, inHarrison's Principles of Internal Medicine, Eighth Ed., Thorn et al., (Eds.), McGraw-Hill, New York, NY, 1977, pp. 2048-2080.
Glowacki et al., “Cell Shape and Phenotypic Expression in Chondrocytes,”Proc. Soc. Exp. Biol. Med. 172(1):93-98, Jan. 1983.
Goldberg et al., “Lipids and Biomineralization-An Overview,”Prog. Histochem. Cytochem., 31(2):1-187, 1996.
Green et al., “Mitochondria and Apoptosis,”Science 281:1309-1312, Aug. 28, 1998.
Green, “Apoptotic Pathways: The Roads to Ruin,”Cell 94:695-698, Sep. 18, 1998.
Gunter et al., “Mechanisms by Which Mitochondria Transport Calcium.”Am. J. Physiol. 27(5Pt1): C755-C786, May. 1990.
Gunter et al., “Mitochondrial Calcium Transport: Physiological and Pathological Relevance,”,Am. J. Physiol. 267(2Pt1):C313-C339, Aug. 1994.
Gunter et al., “The Ca2+Transport Mechanisms of Mitochondria and Ca2+Uptake From Physiological-Type Ca2+Transients,”Biochim. Biophys. Acta 1366:5-15, 1998.
Gunter et al., “Transport of Calcium by Mitochondria,”J. Bioenerg. Biomembr. 26(5):471-485, 1994.
Hyc et al., “Immunological Response Against Allogeneic Chondrocytes Transplanted Into Joint Surface Defects in Rats,”Cell. Transplant. 6(2):119-124, Mar.-Apr. 1997.
Indiveri et al., “Kinetic Characterization of the Reconstituted Dicarboxylate Carrier from Mitochondria: a Four-Binding-Site Sequential Transport System,”Biochim. Biophys. Acta 1143(3):310-318, Jul. 26, 1993.
Iacobazzi et al., “Cloning and Sequencing of the Bovine cDNA Encoding the Mitochondrial Tricarboxylate Carrier Protein,”Biochim. Biophys. Acta 1284(1):9-12, Oct. 2, 1996.
Je{hacek over (z)}ek et al., “Mammalian mitochondrial uncoupling proteins.”Int J Biochem Cell Biol 30(11):1163-1168, Nov. 1998.
Johnson et al., “Matrix Vesicle Plasma Cell Membrane Glycoprotein-1 Regulates Mineralization by Murine Osteoblastic MC3T3 Cells,”J. Bone Miner. Res. 14(6):883-892, Jun. 1999.
Kapùs et al., “Is the Mitochondrial Ca2+Uniporter a Voltage-Modulated Transport Pathway?,”FEBS Lett. 282:61-64, Apr. 1991.
Karbowski et al., “Cycloheximide and 4-OH-TEMPO Suppress Chloramphenicol-Induced Apoptosis in RL-34 Cells Via the Suppression of the Formation of Megamitochondria,”Biochim. Biophys. Acta 1449(1):25-40, Feb. 4, 1999.
Klingenberg, “Principles of Carrier Catalysis Elucidated by Comparing Two Similar Membrane Translocators from Mitochondria, the ADP/ATP Carrier and the Uncoupling Protein,”Annals New York Academy of Sci
Davis Robert E.
Dykens James A.
Ghosh Soumitra S.
Granston, Jr. Andrew E.
Murphy Anne N.
Ketter James
MIGENIX Corp.
Seed IP Law Group PLLC
The Regents of the University of California
LandOfFree
Methods and compositions for diagnosing and treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for diagnosing and treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for diagnosing and treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3668448